Iron

Evidence Level: L5

Predicted Indications: 5

Iron

Pharmacist Assessment Report

Iron: Vitamin B12- and folate-independent constitutional megaloblastic anemia

One-Sentence Summary

Iron is an essential mineral supplied as oral and injectable products and is central to hemoglobin production. The TxGNN model predicts it may be relevant to vitamin B12- and folate-independent constitutional megaloblastic anemia. No clinical trials and no publications directly studying this disease were found, so the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Vitamin B12- and folate-independent constitutional megaloblastic anemia
TxGNN Prediction Score	0.9989
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for iron are not available in the data compiled for this report. Iron is known to be essential for hemoglobin synthesis and red blood cell production.

Megaloblastic anemia, however, is mainly a disorder of DNA synthesis, typically linked to vitamin B12 or folate. A constitutional form that is independent of both vitamins is unlikely to respond to iron unless iron deficiency is also present. The high score most likely reflects the model’s closeness to other anemia-related conditions rather than a specific, demonstrated mechanism. The mechanistic case is therefore weak, and no studies are available to support it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Iron is marketed in India, and all 20 licence records in the data are valid single-ingredient products. The records are partial, so more may exist. Approved indication text is not recorded in the local data. Five examples:

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 161789	Orofer S 200 Injection	Vial of 10 ml injection	Not recorded
Registration No. 88321	Ferise 20 Injection	Vial of 1 ml injection	Not recorded
Registration No. 184357	Rubired Oral Suspension	Bottle of 150 ml oral suspension	Not recorded
Registration No. 103636	Glonia-XT Tablet	Strip of 10 tablets	Not recorded
Registration No. 13001	Anofer S 50mg Injection	Vial of 2.5 ml injection	Not recorded

Safety Considerations

Conditions requiring caution (flagged in the data compiled for this report, not taken from label text): peptic ulcer disease, hereditary hemochromatosis, hemosiderosis, iron metabolism disorders, Wilson disease, ulcerative colitis, inflammatory bowel disease, hemolytic anemia and gastroenteritis.
Drug interactions: 79 interactions are recorded.
- Major: dolutegravir and bictegravir.
- Moderate (examples): doxycycline, tetracycline, ciprofloxacin, omeprazole, rabeprazole, alendronic acid, risedronic acid, ibandronate, levodopa and deferiprone.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no supporting trials or publications (Evidence Level L5). The biological rationale is also weak, because this form of anemia is not driven by iron deficiency.

To proceed, the following is needed:

Evidence that patients with this condition have a coexisting iron deficiency or an iron-responsive component
Case reports, observational data or early-phase studies of iron in this specific condition
Detailed mechanism-of-action data for iron
Package insert warnings and contraindications from the Indian licences

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.